TNF-mediated toxicity after massive induction of specific CD8+ T cells following immunization of mice with a tumor-specific peptide

Journal of Immunology

Volumn 169, Issue 6, 2002, Pages 3053-3060

  Bilsborough, Janine ^a   Uyttenhove, Catherine ^a   Colau, Didier ^a   Bousso, Philippe ^a   Libert, Claude ^a   Weynand, Birgit ^a   Boon, Thierry ^a   Van den Eynde, Benoit J ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 1; INTERLEUKIN 12; NEUTRALIZING ANTIBODY; PEPTIDE; TETRAMER; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; GENE MUTATION; LYMPHOCYTE DEPLETION; LYMPHOCYTE MIGRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHOCK; T LYMPHOCYTE ACTIVATION;

EID: 0037105414     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.6.3053     Document Type: Article

References (37)

1. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice
2. The expression of mouse gene PIA in testis does not prevent safe induction of cytolytic T cells against a PIA-encoded tumor antigen
3. Identification of a second major tumor-specific antigen recognized by cytotoxic T lymphocytes on mouse mastocytoma P815
4. Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL
5. Induction of a cytolytic T cell response in mice with a recombinant adenovirus coding for tumor antigen P815A
6. CTL response and protection against tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815A
7. The shared tumor-specific antigen encoded by mouse gene PIA is a target not only for cytolytic T lymphocytes but also for tumor rejection
8. Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12
9. Enhancement by IL-12 of CTL response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL
10. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the PIA gene
11. Peptide synthesis. Part 2. Procedures for solid phase synthesis using N-α-fluorenylmethysoxycarbamylamino-acid on polymide supports: Synthesis of substance P and of acyl carrier protein 65-74 decapeptide
12. Mouse tumor rejection antigens P815A and P815B: Two epitopes carried by a single peptide
13. Interleukin-1 and interleukin-1 fragments as vaccine adjuvants
14. - transplantation antigen P198: A point mutation generates a new antigenic peptide
15. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria
16. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro
17. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: Superiority of B7-1 over B7-2 for active tumor immunization
18. Cloning and expression of murine IL-12
19. Facing two T cell epitopes: A degree of randomness in the primary response is lost upon secondary immunization
20. Phenotypic analysis of antigen-specific T lymphocytes
21. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes
22. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill
23. The anti-CD3-induced syndrome: A consequence of massive in vivo cell activation
24. Detection of circulating tumor necrosis factor after endotoxin administration
25. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes
26. CC-3052: A water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-α production
27. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia
28. Tumour necrosis factor. Another chapter in the long history of endotoxin
29. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation
30. T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: Critical role of tumor necrosis factor
31. Induction of tumor necrosis factor, IFN-γ, and acute lethality in mice by toxic and non-toxic forms of lipid A
32. + cell activation to a major mastocytoma rejection antigen, P815AB: Requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide
33. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction
34. T cell priming versus T cell tolerance induced by synthetic peptides
35. Peptide antigen treatment of naive and virus-immune mice: Antigen-specific tolerance versus immunopathology
36. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-Al
37. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma